Ascierto PA - Search Results

1

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.

Motti ML, Minopoli M, Di Carluccio G, Ascierto PA, Carriero MV. Motti ML, et al. Among authors: ascierto pa. Int J Mol Sci. 2020 Jun 26;21(12):4544. doi: 10.3390/ijms21124544. Int J Mol Sci. 2020. PMID: 32604720 Free PMC article. Review.

2

3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma.

Ascierto PA, Palmieri G, Parasole R, Daponte A, Castello G. Ascierto PA, et al. Int J Mol Med. 1999 Mar;3(3):303-6. doi: 10.3892/ijmm.3.3.303. Int J Mol Med. 1999. PMID: 10028056 Clinical Trial.

3

Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group.

Ascierto PA, Palmieri G, Strazzullo M, Daponte A, Botti G, Satriano SM, Motti ML, Mozzillo N. Ascierto PA, et al. Ann Oncol. 2000 Apr;11(4):487-90. doi: 10.1023/a:1008375418507. Ann Oncol. 2000. PMID: 10847472 Free article. No abstract available.

4

Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group.

Palmieri G, Pirastu M, Strazzullo M, Ascierto PA, Satriano SM, Motti ML, Botti G, Mozzillo N, Castello G, Cossu A, Lissia A, Tanda F. Palmieri G, et al. Among authors: ascierto pa. Recent Results Cancer Res. 2001;158:200-3. doi: 10.1007/978-3-642-59537-0_20. Recent Results Cancer Res. 2001. PMID: 11092047

5

NF-κB as potential target in the treatment of melanoma.

Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA. Madonna G, et al. Among authors: ascierto pa. J Transl Med. 2012 Mar 20;10:53. doi: 10.1186/1479-5876-10-53. J Transl Med. 2012. PMID: 22433222 Free PMC article. Review.

6

The role of BRAF V600 mutation in melanoma.

Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. Ascierto PA, et al. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. J Transl Med. 2012. PMID: 22554099 Free PMC article.

7

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Ascierto PA, et al. J Transl Med. 2012 May 28;10:107. doi: 10.1186/1479-5876-10-107. J Transl Med. 2012. PMID: 22640478 Free PMC article.

8

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.

Gentilcore G, Madonna G, Mozzillo N, Ribas A, Cossu A, Palmieri G, Ascierto PA. Gentilcore G, et al. Among authors: ascierto pa. BMC Cancer. 2013 Jan 14;13:17. doi: 10.1186/1471-2407-13-17. BMC Cancer. 2013. PMID: 23317446 Free PMC article.

9

Novel approaches in melanoma prevention and therapy.

Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA. Grimaldi AM, et al. Among authors: ascierto pa. Cancer Treat Res. 2014;159:443-55. doi: 10.1007/978-3-642-38007-5_25. Cancer Treat Res. 2014. PMID: 24114495 Review.

10

Side effects and toxicities of targeted therapies in stage IV melanoma.

Ascierto PA, Bastholt L, Hersey P, Cinat G, Eggermont AM, Hauschild A, Espinosa E, Robert C. Ascierto PA, et al. Am J Ther. 2015 Jan-Feb;22(1):44-53. doi: 10.1097/MJT.0b013e3182a39858. Am J Ther. 2015. PMID: 24185314 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

684 results

Search Page